

THE BRITISH ASSOCIATION OF UROLOGICAL SURGEONS

SECTION of ONCOLOGY

BAUS Cancer Registry Analyses of Complex Operations January 1st – 31st December 2009

May 2010

MEMBERS OF THE EXECUTIVE COMMITTEE

M Aitchison	G Boustead	J Crew	D R Greene
R C Kocklebergh	R A Persad	S Prescott	
V Srinivasin	K S Swami		

Copyright

It is important to remind you that, under the Copyright Designs and Patents Act 1988 (CDPA) copyright of this Report, including the charts produced in it, is owned by The British Association of Urological Surgeons Limited (BAUS). Copying or reproducing any part of this material in any other publication without seeking the prior permission of BAUS is a breach of copyright.

Please contact Mrs Sarah Fowler (E-mail: sarah@sarahfowler.org) if you wish to seek the prior consent or licence of BAUS in respect of the above or wish to seek further advice.

PRODUCED FOR BAUS SECTION OF ONCOLOGY by

Mrs Sarah Fowler BAUS Cancer Registry & Audits Manager

CONTENTS

	Page Number
Introduction	1
Results Summary & Methods of analysis	2
A. Cystectomies Charts 1 – 24	3
B. Radical Prostatectomies Charts 25 – 50	15
C. Nephrectomies Charts 51 – 72	28
D. Participating Hospital Centres	39

Introduction

The 2009 analysis of the complex urological operation database is the first extracted from the web-based database developed by Nuvola. This has been the first opportunity to interrogate the database to any significant degree and has not been without its problems. As in previous years, data collection appears to be rather erratic, with the number of cystectomies and nephrectomies reported declining, while the number of radical prostatectomies increased by almost 60%.

The BAUS Registry is still not showing convincing evidence that centralisation of complex pelvic cancers is working effectively. The number of cystectomies per consultant per centre appears to be declining, although on the prostatectomy front the trend is encouragingly upward. Whether this is a true reflection of the situation nationally is unclear, and further comprehensive data is being gathered which we hope to share and discuss at our section meeting in London in the autumn.

Certain trends noted over the last few years appear to continue. These show bladder cancer patients still being offered low rates of continent urinary diversion, although there is a slight upward trend. Extended pelvic lymph node dissection continues to rise, albeit slowly. On the prostate cancer front, the number of cases detected by screening and case finding continues to rise, with the number of T1c cancers now approaching 50%. Laparoscopic radical prostatectomy continues to rise from 36% in 2008 to almost 60%, while about 10% of cases of RP were performed with robotic assistance. One would expect this figure to rise significantly over the next few years. The nephrectomy database has also confirmed an increasing proportion of procedures carried out laparoscopically. In addition to this the proportion of T3 and T4 renal cancers coming to surgery appears to have risen significantly. Whether this is due to the availability of effective adjuvant therapy is unclear but remains an interesting trend to be watched. Lastly the number of patients having accurate follow up data recorded remains disappointingly low, and members of the executive committee are meeting regularly with the South West Cancer Intelligence Service (SWCIS) and the NCIN to look at ways of sharing information, particularly outcome data.

As always Sarah Fowler and the Nuvola team deserve heaps of praise for coping with an extremely busy year getting the system on line and all the users up to speed.

Greg Boustead May 2010

Audit Results Summary

BAUS Complex Operations Datasets – January 1st – December 31st 2009

- 519 cystectomies reported by 77 consultants from 57 centres
- 76% males (388/511 recorded)
- 1757 prostatectomies reported by 92 consultants from 68 centres
- 1482 nephrectomies reported by 138 consultants from 83 centres
- 63% males (911/1440 recorded)

Private patients accounted for 0.2% (1/519) of the cystectomies; 1.7% (30/1757) of the radical prostatectomies and 0.3% (4/1482) of the nephrectomies.

How were the data analysed?

All information presented here was extracted from the web-based database developed by Nuvola and launched in June 2009. All historical information was uploaded to the system at this time and participants were then encouraged to start entering their data directly, either in the form of bulk uploads or on an individual patient basis. As would be expected there have been a number of teething problems both with the bulk uploading and with individual data entry as users become used to the new system.

Until January 1st 2010 data could be returned either by completion of pro formas for each patient or in electronic format using either an Access (Microsoft) database or "in-house" database. The pro formas were entered directly into an Access database, at which time validation comprising mainly of checks for duplicate entries and dates could be carried out. There are separate pro formas for the operation and follow-up information. All of this data was transferred to the web-based system and has been included in the analyses.

The data presented here are a summary of the data extracted from the web-based database on 26th April 2010 and relate to operations performed during the whole of 2009. Follow-up information was returned on 14.1% (73/519) of the cystectomies; 19.6% (344/1757) of the radical prostatectomies and 12.2% (181/1482) of the nephrectomies.

For the ranked charts (1, 2, 21, 22, 25, 26, 47, 48, 51, 52, 69 & 70) the individual consultant or centre identification numbers were removed and replaced with rank numbers starting at 1. A unique, confidential "Ranking Sheet" was prepared for each surgeon to enable them to identify their rank in every chart. For those charts where overall figures for the entire database are shown the ranking sheet displays the consultant's individual figures. No one else can identify the results of an individual consultant. The ranked charts comprise single bars ranked from left to right in the ascending order of the data item being measured with, in addition, the 25, 50, and 75 percentiles. Where percentages are included figures have been rounded up to one decimal point.

A personal ranking sheet for each consultant for each of the three procedures was issued individually to go with this chart book.

Sarah Fowler BAUS Cancer Registry (BCR) Manager May 2010

A. Cystectomies for malignant disease

Chart 1





Chart 2



Total Number of Cystectomies Reported per Centre Median: 4 (Interquartile Range 1 - 14)

Indication	Number & percentage of total (541)	
	Ν	%
Muscle invasive TCC	254	48.9
Uncontrolled superficial disease	84	16.2
Salvage after radiotherapy	17	3.3
Squamous cell Ca	16	3.1
Primary CIS	14	2.7
Gynaecological Ca	9	1.7
Primary adenocarcinoma	8	1.5
Sarcoma	3	0.6
Secondary adenocarcinoma	2	0.4
Other	30	5.8
Not Recorded	82	15.8

Indication for Cystectomy

Chart 4

Cystectomy Pre-operative Clinical Staging Staging could be estimated in 67.6% (351/519) cases

Known Staging	Total Known	
	Ν	%
Stage 0a		
(Ta N0 M0)	14	4.0
Stage 0is		
(Tis N0 M0)	17	4.8
Stage I		
(T1 N0 M0)	71	20.2
Stage II		
(T2a, 2b N0 M0)	129	36.8
Stage III		
(T3a, 3b, 4a N0 M0)	83	23.6
Stage IV	37	10.5
(T4b N0 M0		10.5
Any T N1, N2, N3 M0	including 6	17
Any T any N M1)	with metastases	1.7



Cystectomy - Comparison of Pre-operative clinical & pathological Categories

Chart 6

Cystectomy - Comparison of Pre-operative clinical & Postoperative pathological staging



Cystectomy - Pre-operative Imaging Total Numbers Reported with those as only Imaging method in () Information recorded in 88% cases (456/519)

Imaging Method	N
CT Scan	240 (84)
MRI	96 (12)
Bone Scan	39 (1)
IVU	31 (2)
Others	84 (7)
None	185 (185)

Chart 8

Cystectomy - Pre-operative Serum Creatinine

Serum Creatinine Level µmols/l	Ν	% of total (519)	
0 – 120 µmols/l	393	75.7	
121 - 200 μmols/l	67	12.9	
> 200 µmols/l	8	1.5	
Not recorded	51	9.8	

Cystectomy - Other Pre-operative findings

	N	% of total reporting
Pre operative Radiotherapy		
	32/393	8.1
Pre operative Neoadjuvant		
Chemotherapy	122/404	30.2
Synchronous Upper tract disease		
	17/464	3.7

Chart 10

Status	Number & percentage of total reported (519)	
	Ν	%
Normal	327	63.0
Tumour	7	1.3
Hydronephrosis – left	31	6.0
Hydronephrosis – right	41	7.9
Hydronephosis – bilateral	21	4.0
Non – functioning kidney	4	0.8
Other	12	2.3
Not recorded	76	14.6

Cystectomy - Status Upper Tracts

Cystectomy Pre-operative Potency

	Ν	% of total (519)
Impotent	63	12.1
Partially potent	53	10.2
Fully potent	117	22.5
Potency not recorded	286	55.1

Chart 12

	Ν	% of total (519)
Complete	292	56.3
Minor stress leakage	15	2.9
1 pad per day	0	-
> 1 pad per day	5	1.0
Appliance	20	3.9
Continence not recorded	187	36.0

Cystectomy Pre-operative Continence

	Total	% of	Supervised	%
	Number	total	training	
		(519)	operation	
Consultant				
	448	86.3	159/367	43.3
Specialist Registrar				
	37	7.1	26/37	70.2
Other				
	28	5.4	1/28	3.6
Surgeon not recorded				
-	6	1.2	-	-

Cystectomy Grade of Main Operating Surgeon with numbers & percentage reported as being a supervised training operation

Chart 14

Cystectomy - Diversion procedure 56 laparoscopic procedures were reported* 73 combined synchronous urethrectomies 29 combined synchronous nephroureterctomies

	N	% of total (519)
Ileal conduit		
	381	73.4
Orthotopic		
_	39	7.5
Rectal diversion		
	0	0.0
Continent cutaneous diversion		
	8	1.5
Other		
	9	1.7
Not recorded		
	82	15.8

64.1% (25/39) of the orthotopics were Studer

* Includes 15 performed robotically (da Vinci)

Cystectomy Lymph Node Dissection

	Ν	% of total (519)
None	100	19.3
Palpable only	32	6.2
Below bifurcation of common		
iliac	179	34.5
Extended above bifurcation of		
common iliac	121	23.3
Not recorded	87	16.8

Chart 16

Cystectomies

•	Median duration of operation:
•	All patients = 285 mins; Range: $60 - 675$; (378 patients) Patients having LND = 300 mins; Range: $60 - 675$; (298 patients) Patients with no LND = 278 mins; Range: $60 - 592$; (72 patients)
•	Median number of units of blood transfused = 0 Range: 0 - 10 (reported in 83.0% (431) patients)
•	Median measured blood loss = 500 mls Range: 0 – 6,500 (reported in 88.2% (458) patients)
•	Median post-operative stay = 14 days (excluding deaths)

Median post-operative stay = 14 days (excluding deaths) Range: 0 - 227 (reported in 63.6% (330) patients)

		Ν	%
Intra-operative complications:		55/470	11.7
	Bleeding	6/470	1.3
	Rectal Injury	4/470	0.9
	Iliac vein injury	3/470	0.7
	Other / NR	32/470	6.8
Post-operative complications:		116/414	28.0
	Infections/		
	Septicaemia	25/414	6.0
	Prolonged Ileus	23/414	5.6
	Leaks	12/414	2.9
	Bleeding	6/414	1.5
	Other / NR	50/414	12.1

Cystectomies Complications

Chart 18

Cystectomy - Significance of Complications Overall morbidity Rate = 28.7% (149/519) 30 day mortality Rate = 0.96%(5/519)

	Intra-o	operative	Post-operative			
	Ν	%	Ν	%		
No action required	2	3.6	5	4.3		
Contributed to death	2	3.6	6	5.2		
Delayed discharge	7	12.7	36	31.0		
Required medical treatment	11	20.0	41	35.3		
Required surgery	4	7.3	13	11.2		
Not recorded	29	52.7	15	12.9		

Cystectomy - Operative Histology reported in 12.7% (66/519) cases

Histology	Number & percen known (66)	Number & percentage of total known (66)				
	N	%				
No cancer	6	9.1				
Muscle invasive TCC	37	56.1				
SCC	3	4.5				
Primary CIS	5	7.6				
Sarcoma	0	-				
Gynaecological ca	3	4.5				
Primary adenocarcinoma	1	1.5				
Secondary adenocarcinoma	0	-				
Other	11	16.7				

Chart 20

Cystectomy Follow ups

Follow up recorded in 14.1% (73 / 519) patients

Median time to latest Follow-up = 81 days; range 11 – 399 days

Median number of Follow-ups = 0; Range: 0 - 2

Time to latest follow-up:

Time from Operation to follow-up	Ν	% of total (73)
0 – 90 days	43	58.9
91 – 180 days	23	31.5
181 – 360 days	6	8.2
>=361 days	1	1.4



Chart 22



13

Cystectomy - Current Status Follow up recorded in 14.1% (73 / 519) patients Median time to latest Follow-up = 81 days; range 11 – 399 days

	N	% of total (73)
Alive with no evidence of bladder		
cancer	65	89.0
Alive with local recurrence of		
bladder cancer	1	1.4
Alive with lymph node		
involvement	2	2.7
Alive with metastatic disease	2	2.7
Dead	1	1.4
Not recorded	2	2.7

Late complications were reported in 16/73 (21.9%) patients

Chart 24

Cystectomy - Current Status Follow up recorded in 14.1% (73 / 519) patients Median time to latest Follow-up = 81 days; range 11 – 399 days

Time to follow up	Ν	% of	0 – 90 days		91-180 days		181 – 360 days		>=361 days	
		total	Ν		Ν		Ν		Ν	
		(73)		%		%		%		%
Alive with no evidence of										
bladder cancer	65	89.0	38	90.5	21	87.5	5	83.3	1	100.0
Alive with local recurrence of										
bladder cancer	1	1.4	0	-	0	-	1	16.7	-	
Alive with lymph node										
involvement by bladder ca	2	2.7	1	2.4	1	4.2	0	-	-	
Alive with metastatic disease	2	2.7	2	4.8	0	-	0	-	-	
Dead	1	1.4	0		1	12	0			
	1	1.4	U	-	1	4.2	U	-	-	
Not recorded	2	2.7	1	2.4	1	4.2	0	-	-	

B. Radical Prostatectomies

Chart 25

Total Number of Prostatectomies Reported per Consultant Median: 10 (Interquartile Range 4 - 21)



Chart 26

Total Number of Prostatectomies Reported per Centre Median: 12 (Interquartile Range 3 - 34)





Percentage Age Distribution - Prostatectomies Median : 60 Years; Range 35 -80 (n= 1749*)

Age could be calculated when both date of birth and operation date were recorded = 1749/1757 (99.5%)

Chart 28

Presentation	Ν	% of total (1757)
Via Screening or Case Finding	824	46.9
LUTS		
	245	13.9
Other	444	25.3
Not recorded	244	13.9

Prostatectomy Presentation

Other presentation was only recorded in 12.8% (57/444) cases

3.9% (63/1587) were reported as having had a previous TURP

Prostatectomy Pre-operative Clinical Staging
Staging could be estimated in 75.1% (1320/1757) cases

Known Staging	Total Known	
	Ν	%
Stage I (T1a N0 M0)	6	0.5
Stage II	T1,1a,1b – 100	7.6
(T1b, 1c, 1, 2 N0 M0)	T1c - 569	43.1
	T2 – 529	40.1
Stage III		
(T3 N0 M0)	105	8.0
Stage IV	11	0.8
(T4 N0 M0		
Any T N1 M0		
Any T any N M1)		

Prostatectomies Comparison of clinical & pathological staging



Staging of Prostate Tumours by PSA

Numbers falling in each category Pre-operative PSA was recorded in 96.7% patients (1699/1757) Staging could be estimated in 76.6% (1301/1699) of these cases

Known Clinical Staging	Total Patients	PSA 0-5		PSA 6-10		PSA 11-20		PSA 21-5	0	PSA	
	1 attents	N N	%	N	%	N	%	N 21-5	%	N N	%
Stage I T1a N0 M0	6	4	1.5	2	0.3	0	-	0	-	0	-
Stage II T1b, 1c, 1, 2, N0 M0	1180	242	89.6	642	92.1	249	89.9	44	84.6	3	60.0
Stage III T3 N0 M0	104	22	8.1	48	6.9	25	9.0	8	15.4	1	20.0
Stage IV (T4 N0 M0 Any T N1 M0 Any T any N M1)	11	2	0.7	5	0.7	3	1.1	0	-	1	20.0
Totals	1301	270		697		277		52		5	

Chart 32

Gleason Sum Scores by Age Group - Prostatectomies

Number falling into each category Gleason scores were recorded in 86.5% (1519/1757) Age could be recorded in 99.5% (1512/1519) of these

Age Group	Total Patients	Gleason s	sum 2 – 4	Gleason s	sum 5 – 6	Gleason	sum 7	Gleason	sum 8 – 10
	i unemus	Ν	%	Ν	%	Ν	%	Ν	%
< 60	453	0	-	250	55.2	183	40.4	20	4.4
60 - 64	485	0	-	228	47.0	228	47.0	29	6.0
65 - 69	423	0	-	195	46.1	203	48.0	25	5.9
70 – 74	142	0	-	52	36.6	75	52.8	15	10.6
75 – 79	9	0	-	3	33.3	4	44.4	2	22.2
>=80	0	0		0	-	0	-	0	-
Totals	1512	0	-	728	48.2	693	45.8	91	6.0



Gleason Sum Score Related to Age

Gleason scores were recorded in 86.5% (1519/1757)

Chart 34

Prostatectomy Pre-operative Potency

	Ν	% of total (1757)
Impotent	89	5.1
Partially potent	281	16.0
Fully potent	728	41.4
Potency not recorded	659	37.5

Prostatectomy Pre-operative Continence

	N	% of total (1757)
Complete	1191	67.8
Minor stress leakage	15	0.9
1 pad per day	0	-
> 1 pad per day	0	-
Appliance	1	0.1
Continence not recorded	550	31.3

Chart 36

Prostatectomy Grade of Main Operating Surgeon with numbers & percentage reported as being a supervised training operation

	Total	% of	Supervised	%
	Number	total	training	
		(1757)	operation	
Consultant				
	1501	85.4	316/1320	23.9
Specialist Registrar				
	84	4.8	73/81	90.1
Other				
	126	7.2	6/126	4.8
Surgeon not recorded				
-	46	2.6	-	-

Nerve Sparing	N	% of total
• •		(1757)
Bilateral		
	633	36.0
Unilateral		
	317	18.0
None		
	614	34.9
Not recorded		
	193	11.0

Prostatectomy - Procedure Nerve sparing

Chart 38

Prostatectomy Procedure - Approach

	Ν	% of total (1757)
Retropubic		
	906	51.6
Perineal		
	14	0.8
Other		
	106	6.0
Not recorded		
	731	41.6

Prostatectomy Procedure – Laparoscopic Known Conversion rate = 1.4% (13/938)*

Laparoscopic	N	% of total (1757)
Yes	1044	59.4
No	669	38.1
Not recorded	44	2.5

*Conversion reasons were included in 10/13 and included bleeding in 5 cases

203 (11.6%) procedures were performed robotically (da Vinci)

Chart 40

Prostatectomies

•	37.9% had Lymph Node dissection (605/1596 patients)
•	Median duration of operation:
•	All patients = 170 mins; Range: 50 - 420; (1140 patients) Patients having LND = 167 mins; Range: 60 - 360; (425 patients) Patients with no LND = 170 mins; Range: 50 - 420; (692 patients)
•	Median number of units of blood transfused = 0 Range: 0 - 9 (reported in 93.3% (1639) patients)
•	Median measured blood loss = 400 mls Range: 0 – 8,000 (reported in 92.0% (1617) patients)
•	Median post-operative stay = 3 days (excluding deaths)

Range: 0 - 122 (reported in 55% (1001) patients)

	Procedure	Ν	Median	Range
Duration of	Total patients	1140	170	50 - 420
Operation (mins)	Retropubic	643	170	60 - 420
•	Perineal	12	95	70 - 120
	Laparoscopic	736	180	60 - 384
Units of Blood	Total patients	1639	0	0 - 9
Transfused	Retropubic	879	0	0 – 9
	Perineal	13	0	0 - 0
	Laparoscopic	1024	0	0 – 5
Measured Blood Loss	Total patients	1617	200	0 - 8,000
(mls)	Retropubic	833	400	0 - 8,000
	Perineal	13	200	0 - 1,000
	Laparoscopic	986	200	0 - 4,000
Post -op Length of	Total patients	970	3	0 - 122
Stay (days)	Retropubic	533	3	0 - 45
	Perineal	12	3	1 – 11
	Laparoscopic	611	3	0 - 122

Prostatectomies - Procedure

Chart 42

Prostatectomies Complications

		Ν	%
Intra-operative complications:		80/1757	4.5
	Bleeding	14/1757	0.8
	Rectal Injury	6/1757	0.3
	Difficult access/procedure	8/1757	0.5
	Other / NR	52/1757	2.9
Post-operative complications:		113/1757	6.4
	Infections	6/1757	0.3
	Ileus	2/1757	0.1
	Leaks	3/1757	0.2
	Other / NR	102/1156	5.8

Prostatectomy - Significance of Complications Overall morbidity Rate = 9.1% (160/1757) 30 day mortality Rate = 0.05% (1/1757)

	Intra-operative		Post-operativ	
	Ν	%	Ν	%)
No action required	16	33.3	12	14.5
Contributed to death	0	-	0	0.0
Delayed discharge	2	4.2	19	22.9
Required medical treatment	11	22.9	33	39.8
Required surgery	5	10.4	13	15.7
Not recorded	16	33.3	6	7.2

Chart 44





Prostatectomy Pathology

	N	% of total known
Known Positive Lymph		
Nodes	8/287	2.8
Known Seminal Vesical		
Involvement	19/308	6.2

Chart 46

Prostatectomy Follow ups

Follow up recorded in 19.6% (344 / 1757) patients

Median time to latest Follow-up = 92 days; range 9 – 457 days

Median number of Follow-ups = 0; Range: 0 - 4

Time to latest follow-up:

Time from Operation to follow-up	Ν	% of total (344)
0 – 90 days	161	46.8
91 – 180 days	123	35.8
181 – 360 days	52	15.1
>=361 days	8	2.3



Chart 48



Prostatectomy - Current Status Follow up recorded in 19.6% (344 / 1757) patients Median time to latest Follow-up = 92 days; range 9 – 457 days

	N	% of total (391)
Alive with no evidence of prostate		
cancer	313	91.0
Alive with local recurrence of		
prostate cancer	14	4.1
Alive with lymph node		
involvement	1	0.3
Alive with metastatic disease	2	0.6
Dead	1	0.3
Not recorded	13	3.8

Late complications were reported in 2.6% (9/344) patients:

6 Anastamotic strictures

1 Urethral stricture

2 DVT

Chart 50

Prostatectomy - Current Status Follow up recorded in 19.6% (344 / 1757) patients Median time to latest Follow-up = 92 days; range 9 – 457 days

Time to follow up	Ν	% of	0 – 90 da	ays	91-180 d	lays	181 – 3	60 days	>=361	days
		total	Ν		Ν		Ν		Ν	
		(344)		%		%		%		%
Alive with no evidence of										
prostate cancer	313	91.0	138	<i>90.8</i>	121	<i>93.8</i>	47	85.5	7	87.5
Alive with local recurrence of										
prostate cancer	14	4.1	5	3.3	5	3.9	3	5.5	1	12.5
Alive with lymph node										
involvement	1	0.3	1	0.7	0	0.0	0	0.0	0	0.0
Alive with metastatic disease	2	0.6	1	0.7	0	0.0	1	1.8	0	0.0
Dead	1	0.3	1	0.7	0	0.0	0	0.0	0	0.0
Not recorded	13	3.8	6	3.9	3	2.3	4	7.3	0	0.0

C. Nephrectomies

Chart 51

Total Number of Nephrectomies Reported per Consultant Median: 6 (Interquartile Range 2 - 13)



Chart 52

Total Number of Nephrectomies Reported per Centre Median: 11 (Interquartile Range 3 - 23)



	Ν	% of total (1482)
Incidental finding with no		
symptoms	412	27.8
Haematuria	326	22.0
Other:	460	27.2
Weight Loss	28	1.9
Other Ca	15	1.0
Pain	33	2.2
Other/Not recorded	399	26.9
Not recorded		
not recorded	269	18.2

Nephrectomy - Pre-operative presentation

Chart 54

Nephrectomies – Haematology at Presentation

	Ν	Median	Range
Hb (g/L)	892	13	7 – 167
Total WBC (* 10 ⁹ / L)	819	8	2 – 514
Neutrophils (* 10 ⁹ / L)	706	5	2 - 412
Lymphocytes (* 10 ⁹ /L)	468	2	2 – 114
Platelets (* 10 ⁹ / L)	791	268	2 - 3337

Serum Creatinine Level µmols/l	Ν	% of total (1482)
0 – 120 μmols/l	1146	77.3
121 - 200 μmols/l	153	10.3
> 200 µmols/l	18	1.2
Not recorded	165	11.1

Nephrectomy - Pre-operative Serum Creatinine

Chart 56

Nephrectomy Pre-operative Clinical Staging
Staging could be estimated in 69% (1022/1482) cases

Known Staging	Total Known	
	Ν	%
Stage I (T1 N0 M0)	474	46.4
Stage II (T2 N0 M0)	196	19.2
Stage III (T1, T2, T3 N0, N1		
M0)	207	20.3
Stage IV (T4 N0, N1 M0	145	14.2
Any T N2 M0		
Any T any N M1)	including 81 with metastases	7.9



Nephrectomies Comparison of clinical & pathological staging

Chart 58

Nephrectomy Grade of Main Operating Surgeon with numbers & percentage reported as being a supervised training operation

	Total	% of	Supervised	%
	Number	total	training	
		(1482)	operation	
Consultant				
	963	65.0	216/867	24.9
Specialist Registrar				
	169	11.4	153/167	91.6
Other / Not recorded				
	350	23.6	6/153	3.9

Nephrectomy – Procedure

	N	% of total (1482)
Radical Nephrectomy	993	67.0
Partial Nephrectomy	153	10.3
Simple Nephrectomy	46	3.1
Nephroureterectomy	243	16.4
Heminephrectomy	1	0.1
Other	30	2.0
Not Recorded	16	1.1

The vena cava was reported as being explored in 21 cases:

•3 – level 1; 5 – level 2; 1 – level 3; 3 – level 4 and 9 not recorded •5 – liver mobilisation; 2 cardiopulmonary bypass; 2 circulatory arrest; 8 complete excision from IVC

Chart 60

Nephrectomies – Surgical Approach Known Laparoscopic Conversion rate = 5.7% (43/752)*

Approach	N	% of total (1482)
Open	525	35.4
Laparoscopic	957	64.6

* Conversion reasons

•15 due to bleeding

- •11 due to failure to progress
- •17 other / not recorded

Known Staging	Total	Open		Laparoscopic	
	N	N	%	Ν	%
Stage I (T1 N0 M0)	457	337	73.7	120	26.3
Stage II (T2 N0 M0)	181	107	59.1	74	40.9
Stage III (T1, T2, T3 N0, N1					
M0)	198	118	59.6	80	40.4
Stage IV (T4 N0, N1 M0 Any T N2 M0					
Any T any N M1)	140	60	42.9	80	57.1

Nephrectomy Approach by Pre-operative Clinical Staging Staging could be estimated in 69% (1022/1482) cases

Chart 62

Nephrectomies

•	10% had Lymph Node dissection (121/1212 patients)
•	Median duration of operation = 155 minutes Range: 30 - 840 (reported in 74% (1098) patients)
•	Median number of units of blood transfused = 0 Range: 0 - 32 (reported in 72.4% (1073) patients)
•	Median measured blood loss = 100 mls Range: 0 – 10,000 (reported in 69.5% (1031) patients)
•	Median post-operative stay = 5 days (excluding deaths)

Median post-operative stay = 5 days (excluding deaths Range: 0 - 96 (reported in 57.4% (851) patients)

	Procedure	N	Median	Range
Duration of	Total patients	1098	155	30 - 840
Operation (mins)	Open	358	150	45 - 840
-	Laparoscopic	693	167	57 – 575
	LND	107	180	60 - 510
Units of Blood	Total patients	1073	0	0 - 32
Transfused	Open	345	0	0 - 32
	Laparoscopic	681	0	0 – 12
Measured Blood Loss	Total patients	1031	100	0 - 10,000
(mls)	Open	327	200	0 - 10,000
	Laparoscopic	657	50	0 - 3,000
Post -op Length of	Total patients	851	5	0 - 96
Stay (days)	Open	273	7	0 – 78
• • •	Laparoscopic	538	4	0 – 96

Nephrectomies - Procedure

Chart 64

Nephrectomies Complications

		Ν	%
Intra-operative complications:		54/951	5.7
Post-operative complications:		96/951	10.1
	Infections	8/951	0.8
	Respiratory	5/951	0.5
	Ileus	5/951	0.5

42 complications were reported as being Major and 100 Minor

	Intra-o	perative	Post-operative		
	Ν	%	Ν	%	
No action required	5	8.9	14	11.8	
Contributed to death	1	1.8	1	0.8	
Delayed discharge	3	5.4	30	25.2	
Required medical treatment	2	3.6	41	34.5	
Required surgery	6	10.7	20	16.8	
Not recorded	39	69.6	13	10.9	

Nephrectomy - Significance of Complications Overall morbidity Rate = 15.6% (231/1482) 30 day mortality Rate = 1.3% (15/1118)

Chart 66

Nephrectomies – Parenchymal Tumours Predominant cell type Reported in 100% parenchymal tumours (145)

Predominant Cell Type	Ν	% of total
		reported (145)
Clear Cell		
	112	77.2
Papillary		
	13	9.0
Oncocytoma		
	8	5.5
Chromophobe		
	6	4.1
Collecting duct		
	0	-
Other		
	6	4.1

Nephrectomies – Urothelial Tumours Site of Tumour Reported in 96.8% urothelial tumours (30/31)

Site of Tumour	Ν	% of total
		reported (30)
Calyx		
	3	10.0
Pelvis		
	12	40.0
PUJ		
	2	6.7
Ureter		
	8	26.7
Multiple sites		
	5	16.7

Chart 68

Nephrectomy Follow ups

Follow up recorded in 12.2% (181 / 1482) patients

Median time to latest Follow-up = 77 days; range 16 - 423 days

Median number of Follow-ups = 0; Range: 0 - 5

Time to latest follow-up:

Time from Operation to follow-up	Ν	% of total (181)
0 – 90 davs		
91 – 180 davs	97	53.6
181 – 360 days	40	22.1
>-361 dove	38	21.0
>=361 days	6	3.3



Chart 70



Nephrectomy - Current Status Follow up recorded in 12.2% (181 / 1482) patients Median time to latest Follow-up = 77 days; range 16 – 423 days

	N	% of total (181)
Alive with no evidence of renal		
cancer	147	81.2
Alive with local recurrence of		
renal cancer	0	0.0
Alive with lymph node		
involvement	3	1.7
Alive with metastatic disease	15	8.3
Dead	3	1.7
Not recorded	13	7.2

Late complications were reported in 47/266 (17.7%) patients: 7 wound infection 3 wound hernia 12 renal 9 wound pain 21 other

Chart 72

Nephrectomy - Current Status Follow up recorded in 12.2% (181 / 1482) patients Median time to latest Follow-up = 77 days; range 16 – 423 days

Time to follow up	Ν	% of	0 – 90 da	ays	91-180	days	181 - 36	0 days	>=361	days
		total	Ν		Ν		Ν		Ν	
		(181)		%		%		%		%
Alive with no evidence of renal										
cancer	147	81.2	73	73.7	34	82.9	35	97.2	5	62.5
Alive with local recurrence of										
renal cancer	0	-	0	-	0	-	0	-	0	-
Alive with lymph node										
involvement	3	1.7	3	3.0	1	2.4	0	0.0	2	25.0
Alive with metastatic disease	15	8.3	9	9.1	4	<i>9</i> .8	1	2.8	1	12.5
Dead	3	1.7	2	2.0	1	2.4	0	-	0	-
Not recorded	13	7.2	12	12.1	1	2.4	0	-	0	-

D. Participating Hospital Centres

We are grateful to Consultants from the following Centres / Trusts who provided data for the analyses:

Aberdeen Royal Infirmary Leighton Hospital Addenbrooke's Hospital Lincoln & Louth NHS Trust Airedale General Hospital Lister Hospital; Queen Elizabeth II Alexandra Hospital Hospital, Welwyn Altnagelvin Area Hospital Manchester Royal Infirmary Arrowe Park Hospital Mayday University Hospital Barnet & Chase Farm Hospital Milton Keynes General Hospital **Bedford Hospital Morriston Hospital Bradford Royal Infirmary** New Cross Hospital United Bristol Health Care Trust Noble's Isle of Man Hospital **Broomfield Hospital** Norfolk & Norwich Hospital **Buckinghamshire Hospitals NHS Trust** North Bristol NHSTrust (Southmead) North Devon District Hospital Castle Hill Hospital **Causeway Hospital** North Hampshire Hospital **Chesterfield & North Derbyshire** Northampton General Hospital **Churchill Hospital** Nottingham City Hospital City Hospitals Sunderland NHS Foundation Trust **Pinderfields Hospital Derby Hospitals NHS Foundation Trust** Portsmouth Hospitals NHS Trust **Derriford Hospital** Princess Alexandra Hospital, Harlow Diana, Princess of Wales Hospital; Goole & District Queen Elizabeth Hospital, B'ham Hospital; Scunthorpe General Hospital **Queen's Hospital Burton** Doncaster & Bassetlaw Hospitals NHS Trust Royal Alexandra Hospital (Paisley) **Dorset County Hospital Royal Bournemouth Hospital** East Lancashire Hospitals NHS Trust Royal Devon and Exeter Hospital East Sussex Hospitals NHS Trust **Royal Glamorgan Hospital Royal Hallamshire Hospital Freeman Hospital** Royal Infirmary of Edinburgh Gartnavel General Hospital George Eliot Hospital Royal Liverpool University Hospital Glan Clwyd Hospital **Royal Marsden Hospital Glasgow Royal Infirmary Royal Preston Hospital** Gloucestershire Royal Hospital **Royal Shrewsbury Hospital Golden Jubilee National Hospital** Royal Surrey County Hospital; Frimley Great Western Hospital, Swindon Park Hospital Guy's & Thomas's Hospital Royal United Hospital, Bath Hairmyres Hospital Royal West Sussex NHS Trust, St Richard's Harrogate District Hospital Hospital Heart of England NHS FoundationTrust Salford RoyalNHS Foundation Trust Hemel Hempstead General Hospital; Mount Salisbury District Hospital Sandwell District General Hospital Vernon & Watford Hospitals Hereford Hospitals NHS Trust Southampton General Hospital Southend University Hospital NHS Homerton Hospital Huddersfield Royal Infirmary **Foundation Trust** James Cook University Hospital Southern General Hospital James Paget University Hospital Southport & Ormskirk NHS Trust **Kettering General Hospital** St James's University Hospital **Kidderminster General Hospital** St Mary's Hospital, IOW **Stobhill Hospital** King George Hospital Leicester General Hospital

Stracathro Hospital; Perth Royal Infirmary; Ninewells Hospital Taunton And Somerset Hospital Torbay Hospital University Hospital of North Durham University Hospital of North Stafford University Hospital of Wales Walsall Manor Hospital N H S Trust Walsgrave Hospital Warwick Hospital Watford General Hospital West Suffolk Hospital West Wales General Hospital Western General Hospital, Edinburgh Wexham Park Hospital Worcester Royal Infirmary Wrexham Maelor Hospital York District Hospital